State Board of Administration of Florida Retirement System Lowers Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

State Board of Administration of Florida Retirement System cut its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAGet Rating) by 31.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,681 shares of the biotechnology company’s stock after selling 4,060 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Enanta Pharmaceuticals were worth $410,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Signaturefd LLC raised its holdings in Enanta Pharmaceuticals by 86.7% in the first quarter. Signaturefd LLC now owns 392 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 182 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in Enanta Pharmaceuticals by 164.1% in the second quarter. Nisa Investment Advisors LLC now owns 1,207 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 750 shares during the period. Captrust Financial Advisors lifted its holdings in Enanta Pharmaceuticals by 343.8% in the first quarter. Captrust Financial Advisors now owns 852 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 660 shares during the period. KBC Group NV acquired a new stake in Enanta Pharmaceuticals in the first quarter worth about $113,000. Finally, Mutual of America Capital Management LLC lifted its holdings in Enanta Pharmaceuticals by 6.9% in the first quarter. Mutual of America Capital Management LLC now owns 2,629 shares of the biotechnology company’s stock worth $187,000 after purchasing an additional 170 shares during the period. 97.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ENTA has been the subject of a number of research analyst reports. JMP Securities upped their price target on shares of Enanta Pharmaceuticals from $103.00 to $137.00 and gave the company a “market outperform” rating in a report on Tuesday, August 9th. Oppenheimer upped their price objective on shares of Enanta Pharmaceuticals from $53.00 to $59.00 and gave the company a “market perform” rating in a research note on Wednesday, August 10th. Royal Bank of Canada reduced their price objective on shares of Enanta Pharmaceuticals from $67.00 to $66.00 and set a “sector perform” rating for the company in a research note on Tuesday, August 9th. SVB Leerink upped their price objective on shares of Enanta Pharmaceuticals from $44.00 to $50.00 and gave the company a “market perform” rating in a research note on Monday, August 1st. Finally, StockNews.com started coverage on Enanta Pharmaceuticals in a report on Wednesday, October 12th. They issued a “hold” rating on the stock. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $76.29.

Enanta Pharmaceuticals Price Performance

Shares of ENTA opened at $46.82 on Monday. The company has a market capitalization of $970.34 million, a price-to-earnings ratio of -7.99 and a beta of 0.53. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $37.59 and a fifty-two week high of $92.90. The business’s 50-day moving average is $48.92 and its 200-day moving average is $51.44.

Enanta Pharmaceuticals Company Profile

(Get Rating)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

Further Reading

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAGet Rating).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.